These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21811996)

  • 21. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity.
    Lu CC; Wang YC; Lai JH; Lee TS; Lin HT; Chang DM
    Vaccine; 2011 Jan; 29(3):444-50. PubMed ID: 21078406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.
    Aikawa NE; Campos LM; Silva CA; Carvalho JF; Saad CG; Trudes G; Duarte A; Miraglia JL; Timenetsky Mdo C; Viana VS; França IL; Bonfa E; Pereira RM
    J Rheumatol; 2012 Jan; 39(1):167-73. PubMed ID: 22089462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
    Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
    Chao DY; Cheng KF; Hsieh YH; Li TC; Wu TN; Chen CY; Tsai CA; Chen JH; Chiu HT; Lu JJ; Su MC; Liao YH;
    Vaccine; 2011 Jan; 29(4):617-23. PubMed ID: 21095255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC; Guedes LK; Moraes JC; Saad CG; Aikawa NE; Calich AL; França IL; Carvalho JF; Sampaio-Barros PD; Goncalves CR; Borba EF; Timenetsky Mdo C; Precioso AR; Duarte A; Bonfa E; Laurindo IM
    Ann Rheum Dis; 2011 Dec; 70(12):2144-7. PubMed ID: 21859696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.
    Huang Y; Wang H; Wan L; Lu X; Tam WWS
    Medicine (Baltimore); 2016 May; 95(19):e3637. PubMed ID: 27175678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers.
    Mascagni P; Vicenzi E; Kajaste-Rudnitski A; Pellicciotta G; Monti A; Cervi C; Vitalucci R; Toffoletto F
    Med Lav; 2012; 103(3):220-9. PubMed ID: 22838300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and reactogenicity of a monovalent inactivated 2009 influenza A vaccine in adolescents: with special reference to pre-existing antibody.
    Kobayashi M; Ohfuji S; Fukushima W; Maeda A; Maeda K; Fujioka M; Hirota Y
    J Pediatr; 2012 Apr; 160(4):632-637.e1. PubMed ID: 22094234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.
    Carraro G; Naso A; Montomoli E; Gasparini R; Camerini R; Panatto D; Tineo MC; De Giorgi L; Piccirella S; Khadang B; Ceracchi M; De Rosa A
    Vaccine; 2012 Feb; 30(6):1170-80. PubMed ID: 22178096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H1N1 vaccination in pediatric renal transplant patients.
    Kelen K; Ferenczi D; Jankovics I; Varga M; Molnar MZ; Sallay P; Reusz G; Langer RM; Pasti K; Gerlei Z; Szabo AJ
    Transplant Proc; 2011 May; 43(4):1244-6. PubMed ID: 21620100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.
    Leahy TR; Smith OP; Bacon CL; Storey L; Lynam P; Gavin PJ; Butler KM; O'Marcaigh AS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1656-61. PubMed ID: 23682005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F; Laganà B; Biselli R; Donatelli I; Campitelli L; Nisini R; Cardelli P; Rossi F; D'Amelio R
    Vaccine; 2006 Apr; 24(16):3217-23. PubMed ID: 16466833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.